[Intra-arterial docetaxel chemotherapy with high-dose calcitriol in relapsing metastatic prostate cancer].
Ten patients with hormone relapsing metastatic prostate cancer who had been previously treated with extensive radiotherapy for metastasis and chemotherapy including docetaxel and platinum compounds were evaluated to determine the safety and efficacy of docetaxel with high-dose calcitriol and platinum compound combination intra-arterial chemotherapy. Nine patients with ECOG performance status 3 or greater, and 9 with 12-month survival probability less than 0.5 in the CALGB prognostic model, including 3 aged over 80, were assessable for therapeutic results, adverse events and clinical benefit response. Improvement of QOL and relief of the bone pain were seen immediately after the intra-arterial chemotherapy treatment. Considering that high-dose calcitriol and platinum compound combination intra-arterial chemotherapy is easily administered without major toxic events even to outpatients, it will be a treatment option for the clinical benefit of relapsing prostate cancer patients with poor prognoses.
Mitsuhata
Naoki
N
Dept. of Urology, Kure Kyousai Hospital.
Itoh
Seiichi
S
Watanabe
Yuichi
Y
D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000556:secondary*; D002117:Calcitriol / Q000008:administration & dosage*; D000077143:Docetaxel; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D007261:Infusions, Intra-Arterial; D008175:Lung Neoplasms / Q000556:secondary*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011788:Quality of Life; D043823:Taxoids / Q000008:administration & dosage*
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D002117:Calcitriol